1. Scrip
  2. >>Business

Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’

 
• By Anju Ghangurde

Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022.  All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.

accelerate
Glargine Opportunity Builds Up For Biocon • Source: Alamy

Supplies of Biocon, Ltd.’s partnered interchangeable insulin glargine biosimilar (branded Semglee) buoyed earnings momentum for the Indian firm’s biosimilars business in the fiscal third quarter, with “significant uptake” in store in view of several commercial arrangements already in place in the US.

Biocon Biologics’ deputy CEO Shreehas Tambe highlighted recent gains made by partner Viatris Inc. for the product, which received preferred status with Express Scripts in the formulary contracting cycle. This ensured a status “displacing [Sanofi’s] Lantus,” the preferred brand until then

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.